<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, June 4, 2018 (HealthDay News) — For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to chemoendocrine therapy, according to a study published online June 3 in the New England Journal of Medicine<\/i>. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.<\/p>\n
Joseph A. Sparano, M.D., from the Montefiore Medical Center in Bronx, N.Y., and colleagues randomized 69 percent of 9,719 eligible women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer with a midrange recurrence score of 11 to 25 to either chemoendocrine therapy or endocrine therapy alone.<\/p>\n
The researchers found that in the analysis of invasive disease-free survival, endocrine therapy was noninferior to chemoendocrine therapy (hazard ratio for invasive disease recurrence, second primary cancer, or death, 1.08; 95 percent confidence interval, 0.94 to 1.24; P = 0.26). Similar rates of invasive disease-free survival (83.3 and 84.3 in the endocrine-therapy group and chemoendocrine therapy group, respectively), freedom from disease recurrence at a distant site (94.5 and 95.0 percent), or at a distant or local-regional site (92.2 and 92.9 percent), and overall survival (93.9 and 93.8 percent) were seen in the two treatment groups at nine years.<\/p>\n
“Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score,” the authors write.<\/p>\n
Several authors disclosed financial ties to Genomic Health, which partially funded the study; one author holds a patent issued and licensed to Genomic Health.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n